Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Lenvatinib + Belzutifan in Multiple Solid Tumors
2020-005007-40Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, lenvatinib and belzutifan in hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic adenocarcinoma (PDAC) and 2 more, sponsored by Merck & Co. Primary endpoint: Dose-limiting toxicities. Started Jun 2021; status: active.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)biliary cancerNonhematologic neoplasms
Beyond the preview
Go deeper on 2020-005007-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005007-40.